Physician profile
Dudley A Baringer
NPI 1851463731
$1,446.18
in general payments reported to CMS, 2019-2025
27 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.24 · 2020: $117 · 2021: $200 · 2022: $294 · 2023: $183 · 2024: $327 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $272.17 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $208.33 | 2020-2021 | |
| Lilly USA, LLC | $77.22 | 2021-2023 | Mounjaro |
| Abbvie INC. | $76.24 | 2022-2024 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $74.04 | 2024 | Airsupra |
| Exact Sciences Corporation | $71.34 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $65.03 | 2023-2025 | Spravato |
| Astellas Pharma US INC | $61.05 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $58.80 | 2020-2022 | |
| Pfizer INC. | $51.73 | 2019-2025 | |
| Ibsa Pharma INC. | $51.71 | 2021-2023 | Tirosint, Licart |
| Optinose US, INC. | $47.18 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $41.49 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $39.58 | 2023 | Quviviq |
| Ucb, INC. | $27.40 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $24.60 | 2022 | |
| Eisai INC. | $24.58 | 2025 | |
| Alnylam Pharmaceuticals INC. | $22.93 | 2022 | |
| Lundbeck LLC | $20.23 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.06 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.30 | 2025 | Caplyta |
| Amneal Pharmaceuticals LLC | $17.36 | 2024 | Unithroid |
| Arbor Pharmaceuticals, INC. | $17.10 | 2020 | |
| Abbott Laboratories | $15.86 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $15.23 | 2025 | Repatha, Otezla |
| Horizon Therapeutics Plc | $14.32 | 2022 | |
| Tolmar, INC. | $13.30 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dudley Baringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.